Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jürgen Eckhardt
AddedMar 31, 2024
UpdatedMay 31, 2026
Jürgen Eckhardt

Jürgen Eckhardt

Board Member, AMR Action Fund

CrunchbaseLinkedIn

Jürgen Eckhardt's Career

AMR Action Fund
AMR Action Fund

Boston, MA, US

Board Member· Board
Immunitas Therapeutics
Immunitas Therapeutics

Waltham, MA, US

Board Member· Board
Oerth Bio
Oerth Bio

Durham, NC, US

Board Member· Board
Vesigen Therapeutics
Vesigen Therapeutics

Cambridge, MA, US

Board Member· Board
Khloris Biosciences
Khloris Biosciences

South San Francisco, CA, US

Board Member· Board
Triumvira Immunologics
Triumvira Immunologics

Austin, TX, US

Board Member· Board
Joyn Bio
Joyn Bio

Boston, MA, US

Board Member· Board
Metagenomi
Metagenomi

Emeryville, CA, US

Board Member· Board
Dewpoint Therapeutics
Dewpoint Therapeutics

Boston, MA, US

Board Member· Board
eGenesis
eGenesis

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jürgen Eckhardt's Career

AMR Action Fund
AMR Action Fund
Fund152020Boston, MA, US
Board Member· Board

Leadership at AMR Action Fund

Henry B. SkinnerHenry B. SkinnerCEO
Aleks EngelAleks EngelBoard Member
Bill BurnsBill BurnsBoard Member
Immunitas Therapeutics
Immunitas Therapeutics
Series B$97M332019Waltham, MA, US
Board Member· Board

Leadership at Immunitas Therapeutics

Geeta VemuriGeeta VemuriBoard Member
Laura BrassLaura BrassBoard Member
K. Dane WittrupK. Dane WittrupBoard Member
Mario SuvaMario SuvaCo-Founder
Brian HalakBrian HalakBoard Member
Amanda WagnerAmanda WagnerCEO

Similar to Immunitas Therapeutics

Immune-Onc TherapeuticsImmune-Onc TherapeuticsPalo Alto, CA, USCancer Treatmentest. 2016Immune-Onc TherapeuticsPalo Alto, CA, US · est. 2016

California-based Immune-Onc Therapeutics develops therapeutic antibodies for cancer treatment.

Public · $140.1M35
ImmunaiImmunaiNew York City, NY, USBiomarkers, Biotechest. 2018ImmunaiNew York City, NY, US · est. 2018

Immunai, a biotech firm, uses single-cell genomics and ML for high-resolution immune profiling and biomarker discovery.

Series B · $295M167
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
Oerth Bio
Oerth Bio
Series D$55M502019Durham, NC, US
Board Member· Board

Leadership at Oerth Bio

John DombroskyJohn DombroskyCEO
Vesigen Therapeutics
Vesigen Therapeutics
Series B$28.5M422019Cambridge, MA, US
Board Member· Board

Leadership at Vesigen Therapeutics

Paulash MohsenPaulash MohsenCEO
Stephen BrusoStephen BrusoBoard Member
Robert MillmanRobert MillmanCo-Founder
Quan LuQuan LuCo-Founder
Gerald ChanGerald ChanBoard Member

Similar to Vesigen Therapeutics

Vesalius TherapeuticsVesalius TherapeuticsCambridge, MA, USDrug Developmentest. 2019Vesalius TherapeuticsCambridge, MA, US · est. 2019

Vesalius Therapeutics: Innovating drug development to combat major human illnesses.

Series A · $75M35
Strm.BioStrm.BioCambridge, MA, USGene Therapyest. 2019Strm.BioCambridge, MA, US · est. 2019

STRM.BIO: Pioneering efficient, safe, and scalable gene therapy via extracellular vesicles.

Seed · $2.1M19
Carmine TherapeuticsCarmine TherapeuticsCambridge, MA, USGene Therapiesest. 2019Carmine TherapeuticsCambridge, MA, US · est. 2019

Carmine Therapeutics: Pioneering non-viral gene therapies via red blood cell vesicles.

Series A · $3.4M39
Arrakis TherapeuticsArrakis TherapeuticsWaltham, MA, USMedicines, Therapeuticsest. 2015Arrakis TherapeuticsWaltham, MA, US · est. 2015

Waltham-based biotech firm specializing in innovative solutions for global health challenges.

Series B · $113M121
Khloris Biosciences
Khloris Biosciences
Series A$5M132017South San Francisco, CA, US
Board Member· Board

Leadership at Khloris Biosciences

Joseph C. WuJoseph C. WuCo-Founder
Lynne A. BuiLynne A. BuiCo-Founder
Triumvira Immunologics
Triumvira Immunologics
Series A$100M752015Austin, TX, US
Board Member· Board

Leadership at Triumvira Immunologics

Cynthia CollinsCynthia CollinsBoard Member
Brian BloomBrian BloomBoard Member
Elizabeth WilliamsElizabeth WilliamsBoard Member
Widya MulyasasmitaWidya MulyasasmitaBoard Member
Connor McDermottConnor McDermottBoard Member
Paul LammersPaul LammersCEO

Similar to Triumvira Immunologics

Trio PharmaceuticalsTrio PharmaceuticalsSan Diego, CA, USCancer Therapeuticsest. 2018Trio PharmaceuticalsSan Diego, CA, US · est. 2018

Innovative cancer therapeutics company developing affordable, dual-action treatments for enhanced efficacy and reduced toxicity.

Seed · $3.7M30
Tactiva TherapeuticsTactiva TherapeuticsBuffalo, NY, USCancer Treatmentest. 2016Tactiva TherapeuticsBuffalo, NY, US · est. 2016

Tactiva Therapeutics: Specializing in potent dual T cell receptor cancer immunotherapy.

Series A · $35M30
3T Biosciences3T BiosciencesSouth San Francisco, CA, USImmunotherapy, Therapeuticsest. 20173T BiosciencesSouth San Francisco, CA, US · est. 2017

3T Biosciences, founded in 2017, is a California-based immunotherapy company.

Series A · $52M33
Tr1xTr1xLos Angeles, CA, USCell Therapyest. 2018Tr1xLos Angeles, CA, US · est. 2018

Tr1x: Pioneering cellular therapies for autoimmune disorders, recalibrating the immune system for long-term tolerance.

Series A · $75M30
Joyn Bio
Joyn Bio
Series A$200M1252017Boston, MA, US
Board Member· Board

Leadership at Joyn Bio

Reshma ShettyReshma ShettyBoard Member
Jason KellyJason KellyBoard Member
Michael MiilleMichael MiilleCEO

Similar to Joyn Bio

Pivot BioPivot BioBerkeley, CA, USAgricultural Productsest. 2010Pivot BioBerkeley, CA, US · est. 2010

Pivot Bio, Inc.: A US-based AgriTech firm innovating plant nutrition by harnessing atmospheric nitrogen.

Series D · $616.9M488
Switch BioworksSwitch BioworksSan Carlos, CA, USFertilizerest. 2022Switch BioworksSan Carlos, CA, US · est. 2022

Switch Bioworks: Engineering symbiotic microbes for sustainable, precision-controlled nitrogen fertilizer production.

Seed · $8.1M11
BioConsortiaBioConsortiaDavis, CA, USBiofertilizers, Crop Protectionest. 2014BioConsortiaDavis, CA, US · est. 2014

BioConsortia Inc.: An agri-biotech firm enhancing fertilizer efficiency, plant growth, and crop breeding.

Series B · $52M45
Metagenomi
Metagenomi
Series B$457M1912016Emeryville, CA, US
Board Member· Board

Leadership at Metagenomi

Risa StackRisa StackBoard Member
Jillian BanfieldJillian BanfieldCo-Founder
Brian ThomasBrian ThomasCEO
Willard DereWillard DereBoard Member
Santhosh PalaniSanthosh PalaniBoard Member

Similar to Metagenomi

Emendo BiotherapeuticsEmendo BiotherapeuticsNew York City, NY, USGene Editingest. 2015Emendo BiotherapeuticsNew York City, NY, US · est. 2015

Emendo Biotherapeutics: Advancing gene therapy with next-gen gene-editing tools for genetic disorders.

Late Stage Private · $317.8M104
Acrigen BiosciencesAcrigen BiosciencesAlameda, CA, USGene Editingest. 2019Acrigen BiosciencesAlameda, CA, US · est. 2019

Acrigen Biosciences: Precision gene-editing tech firm developing therapies for genetic disorders.

Pre-Seed · $1.2M11
Editas MedicineEditas MedicineCambridge, MA, USGene Editing, Therapiesest. 2013Editas MedicineCambridge, MA, US · est. 2013

Editas Medicine, Inc.: A clinical-stage biotech firm pioneering CRISPR-based therapies for rare diseases.

Public · $931.6M226
GenEditGenEditSouth San Francisco, CA, USTherapeutic Deliveryest. 2016GenEditSouth San Francisco, CA, US · est. 2016

GenEdit Inc., a biotech firm in California, innovates CRISPR-based therapeutic delivery systems.

Series A · $67.7M47
Dewpoint Therapeutics
Dewpoint Therapeutics
Series C$287M1612018Boston, MA, US
Board Member· Board

Leadership at Dewpoint Therapeutics

Anthony HymanAnthony HymanBoard Member
Giuseppe CiaramellaGiuseppe CiaramellaBoard Member
Ameet NathwaniAmeet NathwaniCEO
Mark MurckoMark MurckoBoard Member
Amir NashatAmir NashatBoard Member
Richard YoungRichard YoungCo-Founder

Similar to Dewpoint Therapeutics

Faze MedicinesFaze MedicinesCambridge, MA, USTherapeuticsest. 2020Faze MedicinesCambridge, MA, US · est. 2020

Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.

Series A · $81M40
Transition BioTransition BioCambridge, MA, USDrug Discoveryest. 2020Transition BioCambridge, MA, US · est. 2020

Transition Bio: Pioneering biomolecular condensate analysis tech for precise drug discovery.

Series A · $50M50
DeepBiome TherapeuticsDeepBiome TherapeuticsLlanura, MA, USDrug Discoveryest. 2017DeepBiome TherapeuticsLlanura, MA, US · est. 2017

DeepBiome Therapeutics, a US-based biotech firm, leverages deep learning and synthetic biology for innovative drug discovery.

Seed · $2.5M6
Nereid TherapeuticsNereid TherapeuticsBoston, MA, USDrug Discoveryest. 2020Nereid TherapeuticsBoston, MA, US · est. 2020

Nereid Therapeutics: Innovating drug discovery with proprietary technologies for new disease treatments.

Series A · $50M12
eGenesis
eGenesis
Series C$265M1052015Cambridge, MA, US
Board Member· Board

Leadership at eGenesis

Isaac CiechanoverIsaac CiechanoverBoard Member
Bob MoreBob MoreBoard Member
Al WiegmanAl WiegmanBoard Member
Boris NikolicBoris NikolicBoard Member
Julie SunderlandJulie SunderlandBoard Member
Mike CurtisMike CurtisCEO

Similar to eGenesis

ExogenesisExogenesisBillerica, MA, USMedical Devicesest. 2005ExogenesisBillerica, MA, US · est. 2005

Exogenesis Corp., based in Billerica, US, develops and processes implantable medical devices.

Seed · $7.8M17
InscriptaInscriptaBoulder, CO, USGenome Engineeringest. 2015InscriptaBoulder, CO, US · est. 2015

Inscripta: Pioneering scalable digital genome engineering with an advanced, fully automated CRISPR-based platform.

Series A · $463.9M178

Jürgen Eckhardt's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Jürgen Eckhardt

Jim ScopaJim ScopaBoard Member · OneVenturesKris JohnsonKris JohnsonBoard Member · Aphelion CapitalPeter BisgaardPeter BisgaardBoard Member · Outpost MedicineJames SyngeJames SyngeBoard Member · Life360Alex MartinAlex MartinBoard Member · RenalGuard SolutionsB.R. ShettyB.R. ShettyFounder · NMC Healthcare